Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
09 janv. 2023 07h30 HE
|
Reunion Neuroscience Inc.
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and...
Reunion Neuroscience Inc. Provides 2023 Corporate Update
04 janv. 2023 07h30 HE
|
Reunion Neuroscience Inc.
Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical...
Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December
06 déc. 2022 08h00 HE
|
Reunion Neuroscience Inc.
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for...
Reunion Neuroscience Puts in Place At-The-Market Equity Facility
18 nov. 2022 17h05 HE
|
Reunion Neuroscience Inc.
TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative and...
Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results
14 nov. 2022 07h30 HE
|
Reunion Neuroscience Inc.
Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023.Appointed Greg Mayes as President and Chief Executive Officer,...
Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET
07 nov. 2022 07h30 HE
|
Reunion Neuroscience Inc.
TORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative...
Reunion Neuroscience to Present at Upcoming November Conferences
31 oct. 2022 07h30 HE
|
Reunion Neuroscience Inc.
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative...
Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs
24 oct. 2022 07h30 HE
|
Reunion Neuroscience Inc.
TORONTO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative...
Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference
12 oct. 2022 07h30 HE
|
Reunion Neuroscience Inc.
TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel serotonergic psychedelic drug development committed to...
Reunion Neuroscience Inc. Announces Executive Changes
07 oct. 2022 17h30 HE
|
Reunion Neuroscience Inc.
TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating...